Kazushige Ohno
Astellas Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kazushige Ohno.
Journal of Pharmacy and Pharmacology | 1998
Atsuyuki Kohara; Masamichi Okada; Rie Tsutsumi; Kazushige Ohno; Masayasu Takahashi; Masao Shimizu-Sasamata; Jun-Ichi Shishikura; Hiroshi Inami; Shuichi Sakamoto; Tokio Yamaguchi
The in‐vitro pharmacological properties of (2,3‐dioxo‐7‐(1H‐imidazol‐***1‐yl)‐6‐nitro‐1,2,3,4‐tetrahydro‐1‐quinoxalinyl)‐acetic acid monohydrate, YM872, a novel and highly water‐soluble α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionate (AMPA)‐receptor antagonist were investigated.
Bioorganic & Medicinal Chemistry | 2015
Hiroshi Inami; Jun-Ichi Shishikura; Tomoyuki Yasunaga; Kazushige Ohno; Hiroshi Yamashita; Kota Kato; Shuichi Sakamoto
As part of a program aimed at discovering orally active 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonists, we screened our compound library and identified 2-[allyl(4-methylphenyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one (7) as a lead compound that inhibited kainate-induced neurotoxicity mediated by AMPA receptors in rat hippocampal cultures. Structure-activity relationship studies of a series of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives revealed that substituents on the phenyl ring attached to the 2-amino group and the 4H-pyrido[3,2-e][1,3]thiazin-4-one ring system play an important role in inhibitory activity against kainate-induced neurotoxicity. Several analogs bearing a phenyl group with a 4-substituent or five- or six-membered ring fused at the 3,4-positions exhibited potent inhibitory activity against kainate-induced neurotoxicity. Further, some of these compounds exhibited significant suppression of maximal electroshock seizure in mice following oral administration. Of these compounds, 2-[(4-chlorophenyl)(methyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one (16i) (YM928) demonstrated the most potent inhibitory effect with an ED50 value of 7.4mg/kg.
Journal of Pharmacology and Experimental Therapeutics | 2003
Hiroshi Yamashita; Kazushige Ohno; Yoko Amada; Hanae Hattori; Yukiko Ozawa-Funatsu; Takashi Toya; Hiroshi Inami; Jun-Ichi Shishikura; Shuichi Sakamoto; Masamichi Okada; Tokio Yamaguchi
Journal of Pharmacology and Experimental Therapeutics | 2003
Kazushige Ohno; Rie Tsutsumi; Naoyuki Matsumoto; Hiroshi Yamashita; Yoko Amada; Jun-Ichi Shishikura; Hiroshi Inami Shin-Ichi Yatsugi; Masamichi Okada; Shuichi Sakamoto; Tokio Yamaguchi
European Journal of Pharmacology | 2004
Hiroshi Yamashita; Kazushige Ohno; Hiroshi Inami; Jun-Ichi Shishikura; Shuichi Sakamoto; Masamichi Okada; Tokio Yamaguchi
Naunyn-schmiedebergs Archives of Pharmacology | 2004
Hiroshi Yamashita; Kazushige Ohno; Yoko Amada; Hiroshi Inami; Jun-Ichi Shishikura; Shuichi Sakamoto; Masamichi Okada; Tokio Yamaguchi
Archive | 1996
Jun-Ichi Shishikura; Hiroshi Inami; Tomoyuki Yasunaga; Masaaki Hirano; Shuichi Sakamoto; Kazushige Ohno; Masamichi Okada; Shin-ichi Tsukamoto
Archive | 1996
Jun-Ichi Shishikura; Hiroshi Inami; Tomoyuki Yasunaga; Masaaki Hirano; Shuichi Sakamoto; Kazushige Ohno; Masamichi Okada; Shin-ichi Tsukamoto
Japanese Journal of Pharmacology | 1998
Kazushige Ohno; Masamichi Okada; Rie Tsutsumi; Shuichi Sakamoto; Tokio Yamaguchi
Archive | 2003
Kazushige Ohno; Rie Tsutsumi; Naoyuki Matsumoto; Yoko Amada; Jun-Ichi Shishikura; Hiroshi Inami; Shin-ichi Yatsugi; Masamichi Okada; Shuichi Sakamoto